Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2002 Aug;8(8):802-7.
doi: 10.3201/eid0808.010418.

Antecedent treatment with different antibiotic agents as a risk factor for vancomycin-resistant Enterococcus

Affiliations

Antecedent treatment with different antibiotic agents as a risk factor for vancomycin-resistant Enterococcus

Yehuda Carmeli et al. Emerg Infect Dis. 2002 Aug.

Abstract

We conducted a matched case-control study to compare the effect of antecedent treatment with various antibiotics on subsequent isolation of vancomycin-resistant Enterococcus (VRE); 880 in-patients; 233 VRE cases, and 647 matched controls were included. After being matched for hospital location, calendar time, and duration of hospitalization, the following variables predicted VRE positivity: main admitting diagnosis; a coexisting condition (e.g., diabetes mellitus, organ transplant, or hepatobiliary disease); and infection or colonization with methicillin-resistant Staphylococcus aureus or Clostridium difficile within the past year (independent of vancomycin treatment). After controlling for these variables, we examined the effect of various antibiotics. Intravenous treatment with third-generation cephalosporins, metronidazole, and fluoroquinolones was positively associated with VRE. In our institution, when we adjusted the data for temporo-spatial factors, patient characteristics, and hospital events, treatment with third-generation cephalosporins, metronidazole, and fluoroquinolones was identified as a risk factor for VRE. Vancomycin was not a risk factor for isolation of VRE.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Leclercq R, Derlot E, Duval J, Courvalin P. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med. 1988;319:157–61. - PubMed
    1. Uttley AHC, Collins CH, Naidoo J, George RC. Vancomycin-resistant enterococci. Lancet. 1988;1:57–8. 10.1016/S0140-6736(88)91037-9 - DOI - PubMed
    1. Centers for Disease Control and Prevention. National nosocomial infections surveillance (NNIS) report, data summary from October 1986-April 1996, issued May 1996. A report from the National Nosocomial Infections Surveillance (NNIS) system. Am J Infect Control. 1996;24:380–8. 10.1016/S0196-6553(96)90026-7 - DOI - PubMed
    1. Evers S, Casadwall B, Charles M, Dutka-Malen S, Galimand M, Courvalin P. Evolution of structure and substrate specificity in D-alanine:D-alanine ligases and related enzymes. J Mol Evol. 1996;42:706–12. 10.1007/BF02338803 - DOI - PubMed
    1. Van der Auwera R, Pensart N, Korten V, Murray BE, Leclercq R. Influence of oral glycopeptides on the fecal flora of human volunteers: selection of highly glycopeptide-resistant enterococci. J Infect Dis. 1996;173:1129–6. - PubMed

Publication types

MeSH terms